G
Giovanni Barosi
Researcher at University of Pavia
Publications - 352
Citations - 21433
Giovanni Barosi is an academic researcher from University of Pavia. The author has contributed to research in topics: Myelofibrosis & Essential thrombocythemia. The author has an hindex of 69, co-authored 334 publications receiving 19225 citations.
Papers
More filters
Journal ArticleDOI
Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology
Emilio Paolo Alessandrino,Sergio Amadori,Giovanni Barosi,Mario Cazzola,Alberto Grossi,Lucio N. Liberato,Franco Locatelli,Monia Marchetti,Enrica Morra,Paolo Rebulla,Giuseppe Visani,Sante Tura +11 more
TL;DR: Using evidence and consensus, recommendations for the treatment of MDS were issued and allogeneic stem cell transplantation was unanimously considered as the only curative treatment for MDS patients, and recommendations on its use were agreed based on patient's age, risk, clinical features and donor availability.
Journal ArticleDOI
Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia.
Giovanni Barosi,Gianluca Viarengo,Alessandro Pecci,Vittorio Rosti,Giovanna Piaggio,Monia Marchetti,Francesco Frassoni +6 more
TL;DR: The absolute number of CD34(+) circulating cells allows MMM to be distinguished from other Ph(-) CMDs; it is strongly associated with the extent of myeloproliferation and predicts evolution toward blast transformation.
Journal ArticleDOI
The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia.
Giovanni Barosi,Achille Ambrosetti,C Finelli,Alberto Grossi,Pietro Leoni,Nicola Lucio Liberato,Maria Concetta Petti,Enrico Pogliani,Marilena Ricetti,Serena Rupoli,Giuseppe Visani,Sante Tura +11 more
TL;DR: The purpose of this work was to develop a definition of myelofibrosis with myeloid metaplasia using diagnostic criteria that would remain valid within the set of patients with chronic myeloproliferative disorders or myelodysplastic syndromes.
Journal ArticleDOI
Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia
Damiano Rondelli,Giovanni Barosi,Andrea Bacigalupo,Josef T. Prchal,Uday R. Popat,Emilio Paolo Alessandrino,Jerry L. Spivak,B. Douglas Smith,Hans G. Klingemann,Steven M. Fruchtman,Ronald Hoffman +10 more
TL;DR: The use of RIC regimens in allogeneic stem cell transplantation results in prolonged survival in intermediate/high-risk MMM patients.
Journal ArticleDOI
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
Giovanni Barosi,Ruben A. Mesa,Guido Finazzi,Claire N. Harrison,Jean-Jacques Kiladjian,Eva Lengfelder,Mary Frances McMullin,Francesco Passamonti,Alessandro M. Vannucchi,Carlos Besses,Heinz Gisslinger,Jan Samuelsson,Srdan Verstovsek,Ronald Hoffman,Animesh Pardanani,Francisco Cervantes,Ayalew Tefferi,Tiziano Barbui +17 more
TL;DR: Revised recommendations for assessing response in ET and PV are presented by a working group established by ELN and International Working Group-Myeloproliferative Neoplasms Research and Treatment that include new definitions of complete and partial remission that include a standardized symptom assessment form.